|Videos|January 24, 2023
Prevalence of Hypothyroidism in a Commercially Insured US Population: Results by Region
An expert in hypothyroidism management reviews key prevalence data examined across US regions and examined by treatment type from a recent poster presentation highlighting the prevalence of hypothyroidism in a commercially insured US population.
Advertisement
Episodes in this series
Advertisement
Related to this article
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
3
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
4
Building an EHR Pathway to Support Menopause Care in Primary Care
5